Hyderabad based NATCO Pharma Limited has recorded consolidated total revenue of INR 513.0 Crore for the Third quarter ended on 31st December, 2019, as against INR 580.0 Crore for the same period last year. The net profit for the period on a consolidated basis, was INR 104.4 Crore as against INR 159.3 Crore same period last year. The company continues to face margin pressures in its Hepatitis C portfolio.
Natco Pharma Limited is a vertically integrated and R&D focused pharmaceutical company engaged in developing, manufacturing and marketing of finished dosage formulations (“FDF”) and active pharmaceutical ingredients (“APIs”). Our focus is primarily on niche therapeutic areas and complex products. We market and distribute our products in over 40 countries. We sell our FDF products in the United States, India, Europe and the rest of the world (“RoW”). We also operate in certain key geographies through our subsidiaries.
Natco Pharma Limited was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million. With a modest beginning of operations as a single unit with 20 employees, Natco today has seven manufacturing facilities spread across India with dedicated modern research laboratories, capabilities in New Drug Development, etc.